Intensive care unit treatment for patients suffering from COVID-19 : the Neuchâtel experience
SARS-CoV-2 appeared in Switzerland in February 2020 and reached Neuchâtel in March. During 2 months, 43 patients were admitted in the intensive care unit. 55% of ICU admitted patients received mechanical ventilation, 66% of which in prone position. All patients were treated with hydroxychloroquine. The majority of patients received antiretrovirals. One patient was treated with remdesivir. Near half the patients were treated with tocilizumab. One patient received a convalescent plasma obtained from patients who had recovered from COVID-19. The mortality rate was 17%. These results are in line with those from university intensive care units in Switzerland.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Revue medicale suisse - 16(2020), 716 vom: 25. Nov., Seite 2284-2286 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Traitement des patients souffrant de Covid-19 aux soins intensifs : l’expérience neuchâteloise |
|---|
| Beteiligte Personen: |
Haller, Moa-Lina [VerfasserIn] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 30.11.2020 Date Revised 07.12.2022 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM318043084 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318043084 | ||
| 003 | DE-627 | ||
| 005 | 20231225164530.0 | ||
| 007 | tu | ||
| 008 | 231225s2020 xx ||||| 00| ||fre c | ||
| 028 | 5 | 2 | |a pubmed24n1060.xml |
| 035 | |a (DE-627)NLM318043084 | ||
| 035 | |a (NLM)33237646 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Haller, Moa-Lina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Intensive care unit treatment for patients suffering from COVID-19 |b the Neuchâtel experience |
| 246 | 3 | 3 | |a Traitement des patients souffrant de Covid-19 aux soins intensifs : l’expérience neuchâteloise |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 30.11.2020 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a SARS-CoV-2 appeared in Switzerland in February 2020 and reached Neuchâtel in March. During 2 months, 43 patients were admitted in the intensive care unit. 55% of ICU admitted patients received mechanical ventilation, 66% of which in prone position. All patients were treated with hydroxychloroquine. The majority of patients received antiretrovirals. One patient was treated with remdesivir. Near half the patients were treated with tocilizumab. One patient received a convalescent plasma obtained from patients who had recovered from COVID-19. The mortality rate was 17%. These results are in line with those from university intensive care units in Switzerland | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Brunner, Marie-Eve |e verfasserin |4 aut | |
| 700 | 1 | |a Zender, Hervé Olivier |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revue medicale suisse |d 2005 |g 16(2020), 716 vom: 25. Nov., Seite 2284-2286 |w (DE-627)NLM154244252 |x 1660-9379 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2020 |g number:716 |g day:25 |g month:11 |g pages:2284-2286 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2020 |e 716 |b 25 |c 11 |h 2284-2286 | ||